Glenmark Pharmaceuticals Ltd., incorporated in the year 1977, is a Mid Cap company (having a market cap of Rs 13888.32 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-12-2020, the company reported a Consolidated Total Income of Rs 2801.85 Crore, down 4.07 % from last quarter Total Income of Rs 2920.60 Crore and up 1.20 % from last year same quarter Total Income of Rs 2768.52 Crore. Company reported net profit after tax of Rs 248.18 Crore in latest quarter.
Investment Rationale
With improving profitability, the brokerage expects return ratios to move to the mid-teens. It continues to value GNP at 14x 12M forward earnings to arrive at Target Price of INR540. It maintains Neutral on limited upside from current levels
Promoter/FII Holdings
Promoters held 46.6 per cent stake in the company as of Dec 30, 2020, while FIIs held 30.2 per cent, DIIs 7 per cent and public and others 16.2 per cent.
